Relmada Therapeutics Appoints Lisa Nolan, Ph.D. as Senior Vice President of Business Development

Company Continues to Broaden and Strengthen its Senior Leadership Team

NEW YORK, April 8, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has appointed Lisa Nolan, Ph.D. as senior vice president of business development. In this role, Dr. Nolan will be responsible for overseeing alliance and business development activities across the company.

Relmada Therapeutics Corporate Logo

Dr. Nolan has been in the healthcare business for over twenty years in multiple functions including business development, strategic planning, marketing and clinical research. Prior to joining Relmada Therapeutics, she was managing director of the business development and interim management consultancy firm Nolex Advisors LLC.  In this position, she managed business development and licensing projects for a number of public and private companies

"We are very pleased to have Lisa joining us as senior vice president of business development," said Sergio Traversa, CEO of Relmada.  "As a senior-level business development executive with an exceptional deal sheet, she brings strong leadership and broad functional experience to the company. Lisa will be an integral part of our efforts to maximize the opportunities for our wholly owned chronic pain therapy product candidates as we approach planned clinical milestones."

Dr. Nolan previously served as chief business officer with Topigen Pharmaceuticals, a Canadian-based clinical-stage biopharmaceutical company focused on innovative respiratory therapeutics, and was instrumental in the sale of the company to Pharmaxis Ltd in 2010. Prior to that she was vice president of global business development and strategic marketing for Skyepharma PLC, a specialty pharmaceutical company focused on innovative drug delivery technologies, where she led numerous partnering transactions with US and international companies. Dr. Nolan also held senior positions in business development, strategic planning and marketing management at West Pharmaceutical Services, Elan Corporation and Zeneca Pharmaceuticals.

"I look forward to joining Relmada Therapeutics at such an exciting time for the company," said Dr. Nolan. "With a strong pipeline of clinical stage candidates, there is a great opportunity to leverage my experience in business development and strategic marketing to have an immediate impact at the company. I look forward to working with the team as we seek to improve the treatment of chronic pain."

Dr. Nolan holds an M.Sc. in Pharmacy and a Ph.D. in Clinical Pharmacology from Trinity College, Dublin.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine; BuTab, its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at:

Forward-Looking Statements

This news release contains "forward-looking statements."  These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169

Media Contact:
David Salisbury
Berry & Company Public Relations
Tel: 212-253-8881

Logo -

To view the original version on PR Newswire, visit:

SOURCE Relmada Therapeutics, Inc.